Microbix Product Results Being Presented at 2026 PASCV

About this update from Microbix Biosystems Inc.

Microbix Product Results Being Presented at 2026 PASCV MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its clients is presenting results of Microbix made quality assessment products ("QAPs™") that help enable full-process quality management of molecular assays to detect human papillomavirus ("HPV") at 2026 PASCV.2026 PASCV is the annual meeting and principal gathering of the Pan American Society for Clinical Virology, taking place in Clearwater Beach, Florida April 29 to May 1, 2026. The three-day event unites industry leaders and specialists committed to advancing the science and practice of viral diagnostics with a program presenting cutting-edge research, practical insights and real-world applications. Microbix will not be attending or exhibiting at 2026 PASCV due to budget and scheduling constraints. Further information about 2026 PASCV is available at https://www.pascv.org/page/2026_Annual_MeetingAt 2026 PASCV, a Microbix client is presenting its poster titled "Performance evaluation of Microbix HPV swabs on the Alinity m HR HPV." Authored by Mark M. Sasaki and Danijela Lucic of Molecular Diagnostics at Abbott® (Des Plaines, IL) with acknowledged support from Microbix staff, the poster discusses the evaluation and performance results of dry swab samples prepared by Microbix for five (5) HPV genotypes, for use in test verification studies on the Alinity m® platform. The results demonstrated 100% detection, strong reproducibility, tight standard deviations, and room temperature stability for 12 days after sample preparation. The poster will be made available at https://www.microbix.com following its presentation.Microbix QAPs help ensure the accuracy of diagnostic tests, including for bacterial, fungal, parasitic, and viral diseases, and in multiple formats, such as liquid-vials and on Copan® FLOQSwabs®. Additionally, Microbix has its QUANTDx™ line of quantified reference materials to support the development of new assays relating to multiplex/syndromic, viral variant, antimicrobial resistance, genetics, oncology, or molecular pathology tests. The Microbix team engages with test developers, manufacturers, clinical labs, and PT/EQA providers to determine how best to support t...

View stock analysis, news, and events for Microbix Biosystems Inc.